Triclobenzazole-levamisole compound dry suspension and its preparation method
By preparing a trichlorobenzamide-levamisole compound dry suspension, the problems of product stability and transportation were solved, achieving high stability and ease of use, making it suitable for group dosing and industrial production in the veterinary drug field.
Patent Information
- Application Number
- CN202311395749.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-25
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-10-25
AI Technical Summary
Existing trichlorobenzamide-levamisole compound products have low stability, are difficult to store and transport, and have complicated preparation processes. The pill and suspension formulations are inconvenient to use.
A trichlorobenzamide-levamisole compound dry suspension is provided, which is composed of trichlorobenzamide, levamisole, xanthan gum, micronized silica gel, poloxamer 188 and sucrose. It is prepared by grinding, sieving and shaking to form a stable dry state, which is suitable for administration in drinking water or mixed with feed.
It achieves high drug stability and ease of use, avoids the adverse pharmacological effects of organic solvents, is suitable for group administration, and has a simple preparation method suitable for large and small-scale production.
Smart Images

Figure BDA0004514511180000061 
Figure BDA0004514511180000062 
Figure BDA0004514511180000071
Abstract
Description
Technical Field
[0001] This invention relates to the field of veterinary medicine, specifically to a trichlorobenzazole-levamisole compound dry suspension and its preparation method. Background Technology
[0002] Parasitic diseases are a major obstacle to the development of agriculture and animal husbandry in my country, causing huge economic losses to farms and farmers, especially in the breeding of cattle and sheep. When livestock and poultry are infected with parasites such as liver flukes and gastrointestinal nematodes, they may experience slow growth, stunted development, decreased productivity, and even death. Severe outbreaks of parasitic diseases can even threaten human health.
[0003] Trichlorobenzazole (TCBZ) is a novel benzimidazole compound produced in the 1980s by Ciba-Geigy Pharmaceuticals Ltd. in Switzerland. It has been proven that TCBZ has a good insecticidal effect on all stages of larvae and adults of liver flukes in humans and animals, and has been widely used to control liver fluke infection in cattle and sheep.
[0004] Levamisole (LMS) is the levorotatory isomer of tetraimidazole and has a highly effective anthelmintic effect against gastrointestinal nematodes. Levamisole is safe, broad-spectrum, and low in toxicity, showing ideal anthelmintic effects against the larvae and adults of various nematodes in the digestive and respiratory tracts of animals, especially effective against nematode infections in cattle and sheep. Levamisole is also an immune enhancer and can be used to improve the immunity of animals with autoimmune deficiencies.
[0005] Although levamisole (a white to off-white crystalline powder, odorless, bitter taste) is readily soluble in water and ethanol (stable in acidic water, easily decomposes and deteriorates in alkaline water, slightly soluble in chloroform, and very slightly soluble in acetone), trichlorobenzazole (a white or off-white crystalline powder, odorless) is soluble in organic solvents such as methanol and ethyl acetate, but insoluble in water. Therefore, the commonly used dosage forms of trichlorobenzazole in clinical practice are mainly granules, suspensions, and pills.
[0006] During application, pills and granules may be expelled; suspensions present challenges in storage and transportation, as well as low physical stability. These issues can lead to insufficient actual dosage, time-consuming and laborious administration, and inconvenient operation.
[0007] Therefore, producing a dosage form that is stable, easy to store and transport, and simple to prepare has become an urgent problem to be solved in the preparation of trichlorobenzamide-levamisole compound drugs. Summary of the Invention
[0008] To address the aforementioned problems, this invention provides a trichlorobenzazole-levamisole compound dry suspension and its preparation method, thereby resolving issues such as low stability, difficult storage and transportation, and cumbersome preparation processes of trichlorobenzazole-levamisole compound products on the market.
[0009] This invention provides a trichlorobenzamide-levamisole compound dry suspension, which is composed of the following main and excipient ingredients: 4 parts trichlorobenzamide, 3 parts levamisole, 2.2-2.4 parts suspending agent, 1.0-1.4 parts flow aid (internal hygroscopic agent, dispersant), 1.0-1.2 parts emulsifying wetting agent, and 88.0-88.8 parts sweetener (filler).
[0010] The Chinese Pharmacopoeia includes dry suspensions, which are powdered or granular preparations made by adding various excipients to drugs that are poorly soluble or insoluble in water according to the requirements of suspensions. When used, an appropriate amount of water is added and the mixture is shaken to quickly disperse it into a suspension.
[0011] In one embodiment of the compound dry suspension of the present invention, preferably, the suspending agent is xanthan gum; the flow aid is micronized silica gel; the emulsifying wetting agent is poloxamer 188; and the sweetener (filler) is sucrose.
[0012] In a further embodiment of the compound dry suspension of the present invention, preferably, the trichlorobenzamide-levamisole compound dry suspension is composed of the following main and excipient ingredients: 4 parts trichlorobenzamide, 3 parts levamisole, 2.4 parts xanthan gum, 1.2-1.4 parts micronized silica gel, 1.0-1.2 parts poloxamer 188, and 88.2-88.4 parts sucrose.
[0013] In a further embodiment of the compound dry suspension of the present invention, the compound dry suspension is composed of the following main and excipient ingredients: 4 parts of trichlorobenzazole, 3 parts of levamisole, 2.4 parts of xanthan gum, 1.4 parts of micronized silica gel, 1.0 part of poloxamer 188, and 88.2 parts of sucrose.
[0014] In one embodiment of the compound dry suspension of the present invention, the compound dry suspension is obtained by grinding each main and excipient separately and passing them through a 60-mesh sieve, mixing the powders obtained by mixing them in the following weight ratios: 4 parts trichlorobenzazole, 3 parts levamisole, 2.2-2.4 parts xanthan gum, 1.0-1.4 parts micronized silica gel, 1.0-1.2 parts poloxamer 188, and 88.0-88.8 parts sucrose, and then thoroughly shaking them to ensure uniform mixing.
[0015] Another aspect of the present invention provides a method for preparing a trichlorobenzamide-levamisole compound dry suspension, comprising the following steps: (1) placing the main and excipient materials trichlorobenzamide, levamisole, xanthan gum, micronized silica gel, poloxamer 188 and sucrose in a mortar and grinding for 5 minutes to obtain the ground main and excipient materials respectively; (2) passing the ground main and excipient materials through a 60-mesh sieve; (3) weighing the sieved main and excipient materials according to the weight ratio of 4 parts trichlorobenzamide, 3 parts levamisole, 2.2-2.4 parts suspending agent, 1.0-1.4 parts flow aid, 1.0-1.2 parts emulsifying wetting agent and 88.0-88.8 parts sweetener, and placing them in a stoppered medicine bottle; (4) shaking to mix the medicine in the medicine bottle to obtain the compound dry suspension.
[0016] In the method of the present invention, in step (4), oscillation can be performed using an oscillating mixer with a rotation speed of 800 rpm to facilitate the mixing of the main and excipient components of the medicine in the vial.
[0017] In this invention, "wt%" means "weight %".
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] 1. The dry suspension of the present invention contains both trichlorobenzazole and levamisole, which can expand the antiparasitic spectrum of the dry suspension drug, expel liver flukes and gastrointestinal nematodes, and also enhance the immunity of livestock.
[0020] 2. No organic solvents are added to the dry suspension of this invention, thus avoiding the adverse pharmacological effects of organic solvents and ensuring high safety. The dry suspension of this invention is a veterinary drug with a limited variety of components. However, when temporarily prepared and administered as a suspension, the suspension exhibits good physical stability and slow sedimentation, while still meeting the quality requirements of a suspension, resulting in accurate dosage.
[0021] 3. The formulation of the present invention is a dry suspension. Compared with liquid formulations such as suspensions, dry suspensions have better stability. They remain dry throughout the production and storage process and can be sealed in packaging to avoid contact with air and moisture, making them convenient to store, transport and use.
[0022] 4. The dry suspension of the present invention can be administered through drinking water or as a premix in feed, making it convenient to use and suitable for group administration.
[0023] 5. The preparation method of the trichlorobenzamide-levamisole compound dry suspension of the present invention can be prepared by following a specific formula and through simple steps. The method is simple, does not require large-scale instruments, and can achieve large-scale and small-scale repeated production, and has good prospects for industrial production and application. Detailed Implementation
[0024] The present invention will be further illustrated by the following embodiments, and the advantages and features of the present invention will become clearer with the description. However, the scope of protection of the present invention is not limited to the following embodiments. Modifications or substitutions to the details and form of the technical solutions of the present invention can be made without departing from the spirit and scope of the present invention, but all such modifications and substitutions fall within the scope of protection of the present invention.
[0025] In this embodiment of the invention, the main and auxiliary raw materials are all commercially available, and the equipment used is all known equipment.
[0026] Example (Preparation of a trichlorobenzazole-levamisole compound dry suspension pharmaceutical composition)
[0027] Example 1
[0028] Prescription: Triclofenac 0.040g, Levamisole 0.030g, Xanthan Gum 0.022g, Micronized Silica Gel 0.010g, Poloxamer 188 0.010g, Sucrose 0.888g, and filler to 1g.
[0029] Preparation method:
[0030] (1) Place the main and auxiliary materials trichlorfonazole, levamisole, xanthan gum, micronized silica gel, poloxamer 188 and sucrose in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively.
[0031] (2) Pass the ground main and auxiliary materials through a 60-mesh sieve;
[0032] (3) Weigh out 0.400g of sieved trichlorobenzazole, 0.300g of levamisole, 0.220g of xanthan gum, 0.100g of micronized silica gel, 0.100g of poloxamer 188 and 8.880g of sucrose, mix them and place them in a stoppered medicine bottle;
[0033] (4) Use a shaking mixer, set the rotation speed to 800 rpm, mix the drug and take 1g to obtain the target compound dry suspension.
[0034] Example 2
[0035] Prescription: Triclofenac 0.040g, Levamisole 0.030g, Xanthan Gum 0.023g, Micronized Silica Gel 0.014g, Poloxamer 188 0.011g, Sucrose 0.882g, and filler to 1g.
[0036] Preparation method:
[0037] (1) Place the main and auxiliary materials trichlorfonazole, levamisole, xanthan gum, micronized silica gel, poloxamer 188 and sucrose in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively.
[0038] (2) Pass the ground main and auxiliary materials through a 60-mesh sieve;
[0039] (3) Weigh out 0.400g of sieved trichlorobenzazole, 0.300g of levamisole, 0.230g of xanthan gum, 0.140g of micronized silica gel, 0.110g of poloxamer 188 and 8.820g of sucrose, and mix them in a stoppered medicine bottle;
[0040] (4) Use a shaking mixer, set the rotation speed to 800 rpm, mix the drug and take 1g to obtain the target compound dry suspension.
[0041] Example 3
[0042] Prescription: Triclofenac 0.040g, Levamisole 0.030g, Xanthan Gum 0.024g, Micronized Silica Gel 0.012g, Poloxamer 188 0.012g, Sucrose 0.882g, and filler to 1g.
[0043] Preparation method:
[0044] (1) Place the main and auxiliary materials trichlorfonazole, levamisole, xanthan gum, micronized silica gel, poloxamer 188 and sucrose in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively.
[0045] (2) Pass the ground main and auxiliary materials through a 60-mesh sieve;
[0046] (3) Weigh out 0.400g of sieved trichlorobenzazole, 0.300g of levamisole, 0.240g of xanthan gum, 0.120g of micronized silica gel, 0.120g of poloxamer 188 and 8.820g of sucrose, mix them and place them in a stoppered medicine bottle;
[0047] (4) Use a shaking mixer, set the rotation speed to 800 rpm, mix the drug and take 1g to obtain the target compound dry suspension.
[0048] Example 4
[0049] Prescription: Triclofenac 0.040g, Levamisole 0.030g, Xanthan Gum 0.023g, Micronized Silica Gel 0.010g, Poloxamer 188 0.012g, Sucrose 0.885g, and filler to 1g.
[0050] Preparation method:
[0051] (1) Place the main and auxiliary materials trichlorfonazole, levamisole, xanthan gum, micronized silica gel, poloxamer 188 and sucrose in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively.
[0052] (2) Pass the ground main and auxiliary materials through a 60-mesh sieve;
[0053] (3) Weigh out 0.400g of sieved trichlorobenzazole, 0.300g of levamisole, 0.120g of poloxamer 188, 0.230g of xanthan gum, 0.100g of micronized silica gel and 8.850g of sucrose, and mix them in a stoppered medicine bottle;
[0054] (4) Use a shaking mixer, set the rotation speed to 800 rpm, mix the drug and take 1g to obtain the target compound dry suspension.
[0055] Comparative Example 1 (without the addition of the emulsifying wetting agent poloxamer 188)
[0056] Prescription: Triclofenac 0.040g, Levamisole 0.030g, Xanthan Gum 0.023g, Micronized Silica Gel 0.010g, Sucrose 0.897g, and filler to 1g.
[0057] Preparation method:
[0058] (1) Place the main and auxiliary materials trichlorfonazole, levamisole, xanthan gum, micronized silica gel and sucrose in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively;
[0059] (2) Pass the ground main and auxiliary materials through a 60-mesh sieve;
[0060] (3) Weigh out 0.400g of sieved trichlorobenzazole, 0.300g of levamisole, 0.230g of xanthan gum, 0.100g of micronized silica gel and 8.970g of sucrose, mix them and place them in a stoppered medicine bottle;
[0061] (4) Use a shaking mixer, set the rotation speed to 800 rpm, mix the drug and take 1g to obtain the target compound dry suspension.
[0062] Comparative Example 2 (the suspending agent was replaced with sodium carboxymethyl cellulose)
[0063] Prescription: Triclofenac 0.040g, Levamisole 0.030g, Sodium Carboxymethyl Cellulose 0.023g, Micronized Silica Gel 0.010g, Poloxamer 188 0.012g, Sucrose 0.885g, and filler to 1g.
[0064] Preparation method:
[0065] (1) Place the main and auxiliary materials trichlorobenzazole, levamisole, sodium carboxymethyl cellulose, micronized silica gel, poloxamer 188 and sucrose in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively.
[0066] (2) Pass the ground main and auxiliary materials through a 60-mesh sieve;
[0067] (3) Weigh out 0.400g of sieved trichlorobenzazole, 0.120g of poloxamer 188, 0.300g of levamisole, 0.230g of sodium carboxymethyl cellulose, 0.100g of micronized silica gel and 8.850g of sucrose, and mix them in a stoppered medicine bottle;
[0068] (4) Use a shaking mixer, set the rotation speed to 800 rpm, mix the drug and take 1g to obtain the target compound dry suspension.
[0069] Sample testing
[0070] Test method:
[0071] The Chinese Veterinary Pharmacopoeia records the standards for determining the sedimentation volume ratio and redispersibility of oral suspensions. The sedimentation volume ratio is determined as follows: Take five bags of the test sample, pour out the contents, add them to a 50mL stoppered graduated cylinder, add water to the 50mL mark, shake vigorously, and record the initial height (H0) as 50mL. After standing for 0.5h, 1h, 2h, and 3h, record the height (H) of the solution. The H / H0 ratio should not be less than 0.9, which meets the requirements. The redispersibility is determined as follows: Place each sample of dry suspension in a 50mL stoppered graduated cylinder, add water to the 50mL mark, seal the cylinder, shake thoroughly for 1 minute, and let stand. After 7 days of standing, invert the stoppered graduated cylinder and count one 180° rotation as one shake. Each shake is spaced 5s apart. The number of shakes is used to evaluate the redispersibility of the suspension; fewer shakes indicate better redispersibility.
[0072] Test results:
[0073] The sedimentation volume ratios of the trichlorobenzamide-levamisole compound dry suspensions in Examples 1-4 were tested according to the above standards at different times, and the specific data are shown in Table 1 below.
[0074] Table 1. Results of Time-Sedimentation Volume Ratio Test for Samples
[0075]
[0076] The settling volume ratio and redispersibility of the trichlorobenzamide-levamisole compound dry suspensions in Examples 1-4 and Comparative Examples 1-2 were tested according to the above standard at 3 h, and the floating of the drug was observed. The results are shown in Table 2 below.
[0077] Table 2. Sedimentation volume ratio, flotation, and redispersion test results of the samples.
[0078]
[0079]
[0080] As shown in Table 2, the sedimentation volume ratios of the trichlorobenzamide-levamisole compound dry suspensions prepared in Examples 1-4 are all greater than 0.9, and the dispersion is good, with no clumping or floating of the drug, which meets the requirements for dry suspensions.
[0081] Compared with Example 1, the compound dry suspension of Comparative Example 1 produced more agglomeration and floating of the drug, indicating that poloxamer 188 can reduce and improve drug agglomeration and floating.
[0082] Compared with Example 1, Comparative Example 2 showed a very low sedimentation volume ratio, indicating that xanthan gum can achieve a suspending effect, while sodium carboxymethyl cellulose failed to achieve a suspending effect in this dry suspension and is not suitable for this dry suspension.
[0083] The following are single-factor experiments and orthogonal experiments of the active pharmaceutical ingredient and excipients.
[0084] Experimental materials: Trichlorobenzazole, levamisole, micronized silica gel, poloxamer 188, sucrose powder, xanthan gum, sodium carboxymethyl cellulose, and hydroxypropyl methyl cellulose.
[0085] Experimental apparatus: Glass rod, stoppered graduated cylinder (50mL), electronic balance, 80-mesh sieve, spatula, mortar, 60-mesh fecal sieve, copper wire ring and beaker.
[0086] Experimental methods:
[0087] 1. Single-factor experiment (types and amounts of main and auxiliary materials)
[0088] Based on the average sheep weight, drug dosage, daily water intake, and the ratio of compound dry suspension to water (1:50), 4.0% by weight of trichlorfonazole was selected as the amount of trichlorfonazole used in the trichlorfonazole-levamisole compound dry suspension. According to the ratio, the amount of levamisole used in the compound dry suspension was 3.0% by weight.
[0089] (1) Suspending agents
[0090] Each compound dry suspension sample, excluding the suspending agent, contained the following components: 0.040 g of triclobenzazole, 0.030 g of levamisole, 0.005 g of micronized silica gel, 0.005 g of poloxamer, and the remainder sucrose, bringing the total to 1 g. In the sample preparation experiments, both the main and excipient materials were added, keeping the suspending agent as the sole variable. The suspending agents to be tested were xanthan gum, sodium carboxymethyl cellulose, and hydroxypropyl methylcellulose, and nine experimental doses for each suspending agent were determined through preliminary experiments.
[0091] Based on a total weight of 1g of the compound dry suspension, the dosage ratios of different types of suspending agents are shown in Table 3 below.
[0092] Table 3 Types and Dosages of Suspension Agents
[0093]
[0094]
[0095] Preparation method:
[0096] 1) Place trichlorobenzazole, levamisole, xanthan gum, micronized silica gel, sucrose and poloxamer 188 in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively;
[0097] 2) Pass all the ground main and auxiliary materials through a 60-mesh sieve;
[0098] 3) Weigh 0.400g of triclofenac, 0.300g of levamisole, 0.050g of micronized silica gel, 0.050g of poloxamer, each weight percentage of suspending agent and sucrose, fill to 10g, mix and place in a stoppered medicine bottle;
[0099] 4) Use a shaking mixer, set the speed to 800 rpm, mix the drug and take 1g to obtain the compound dry suspension.
[0100] Each group of drugs was placed in a 50mL stoppered graduated cylinder, water was added to the maximum volume, and the dry suspension was tested to determine whether it met the requirements of the Chinese Veterinary Pharmacopoeia.
[0101] Sedimentation volume ratio determination method: Take 50 mL of the test sample using a stoppered graduated cylinder, stopper tightly, shake vigorously for 1 min, and record the initial height H0 of the suspension; let stand for 3 h, and record the final height H of the suspension. For dry suspensions, add water according to the dosage ratio specified under each category and shake to ensure uniform dispersion, and determine the sedimentation volume ratio using the method described above. Calculation formula: Sedimentation volume ratio = H / H0.
[0102] Redispersibility test method: Place each sample of dry suspension in a 50mL stoppered graduated cylinder, add water to the 50mL mark, seal the graduated cylinder with the stopper, shake thoroughly for 1 minute, and then let it stand. After standing for 7 days, invert the stoppered graduated cylinder and count one 180° rotation as one shake. Each shake is spaced 5 seconds apart. The number of shakes is used to evaluate the redispersibility of the suspension. The fewer the number of shakes, the better the redispersibility of the suspension.
[0103] The results are shown in Table 4-6 below.
[0104] Table 4. Results of xanthan gum determination
[0105]
[0106]
[0107] When the xanthan gum dosage was 2.2%, 2.3%, and 2.4%, the sedimentation volume ratios were 0.92, 0.94, and 0.98, respectively. All three sedimentation volume ratios were greater than 0.90, and the redispersibility did not exceed 10 times. Therefore, the xanthan gum dosage in the dry suspension can be selected from 2.2%, 2.3%, or 2.4%.
[0108] Table 5. Results of sodium carboxymethyl cellulose determination
[0109]
[0110] In the single-factor dosage determination of sodium carboxymethyl cellulose in 9 groups, when the sodium carboxymethyl cellulose dosage was 4.0%, the sedimentation volume ratio reached the maximum value in the group, but it was only 0.68, indicating that the sedimentation was relatively serious.
[0111] Table 6 Results of Hydroxypropyl Methylcellulose Determination
[0112]
[0113] In these nine groups of single-factor dosage determinations of hydroxypropyl methylcellulose, when the dosage of hydroxypropyl methylcellulose was 1.0%, the sedimentation volume ratio reached the maximum value within the group, but it was only 0.52, not 0.90, indicating that sedimentation was still relatively severe.
[0114] According to the requirements of the Chinese Veterinary Pharmacopoeia, the sedimentation volume ratio of oral suspensions should not be less than 0.90.
[0115] Only when the sedimentation volume ratio of xanthan gum meets the standard for dry suspension, and considering issues such as cost and operation, is xanthan gum preferred as a suspending agent for trichlorobenzamide-levamisole compound dry suspension.
[0116] (2) Polosham 188
[0117] Each compound dry suspension sample, excluding poloxamer 188, contained the following components: 0.040 g of triclobenzazole, 0.030 g of levamisole, 0.022 g of xanthan gum, 0.005 g of micronized silica gel, and the remainder sucrose, bringing the total to 1 g. In the sample preparation experiments, both the main and excipients were added, keeping poloxamer 188 as a single variable.
[0118] Based on a total weight of 1g of the compound dry suspension, the specific dosage ratio of poloxamer 188 is as follows:
[0119] Table 7. Different doses of poloxamer 188
[0120]
[0121] Preparation method:
[0122] 1) Place the main and auxiliary materials trichlorfonazole, levamisole, xanthan gum, micronized silica gel, sucrose and poloxamer 188 in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively.
[0123] 2) Pass all the ground main and auxiliary materials through a 60-mesh sieve;
[0124] 3) Weigh out 0.400g of sieved trichlorobenzazole, 0.300g of levamisole, 0.050g of micronized silica gel, 0.220g of xanthan gum, 18g of each weight of poloxamer and the remaining sucrose, and fill to 10g. Mix and place in a stoppered medicine bottle.
[0125] 4) Use a shaking mixer, set the speed to 800 rpm, mix the drug and take 1g to obtain the compound dry suspension.
[0126] Each group of drugs was placed in a 50mL stoppered graduated cylinder, and water was added to the maximum volume. The emulsification effect of the excipients was evaluated by measuring the sedimentation volume ratio of the dry suspension and by observing whether there was any drug floating on the surface of the suspension. The results are shown in Table 8 below.
[0127] Table 8. Suspension of poloxamer 188 dry suspension at different dosages
[0128]
[0129]
[0130] When the dosage of poloxamer 188 was 1.0%, 1.1%, and 1.2%, the sedimentation volume ratio reached or approached 0.90, which met the requirements, and no clumping or floating of the drug occurred in the suspension.
[0131] (3) Micronized silica gel
[0132] To improve the flowability of the trichlorobenzylazole-levamisole compound dry suspension in its solid state, micronized silica gel was added, and the angle of repose of the solid powder was measured. The angle of repose is the maximum angle formed between the free inclined plane of the powder accumulation layer and the horizontal plane in a static equilibrium state. The flowability of the dry suspension was evaluated using a fixed funnel method for measuring the angle of repose. The specific measurement method is as follows:
[0133] Fix the funnel to the iron stand, invert the petri dish on the table, and measure the height of the petri dish as h and the radius as r. Align the center of the petri dish with the funnel outlet, maintaining a 10cm gap between the center and the bottom of the funnel. Pour each portion of the dry suspension, prepared by mixing the main and auxiliary materials, into the funnel. The dry suspension will drip from the funnel into the inverted petri dish below. The dry suspension will form a cone on the petri dish. Stop pouring the dry suspension when the edge of the cone just reaches the edge of the petri dish. Measure the height of the cone formed by the dry suspension as H.
[0134] The formula for calculating the angle of repose is as follows:
[0135]
[0136] Repeat the measurement three times and calculate the average value of the angle of repose. Under normal circumstances, the smaller the angle of repose, the better the flowability. When α≤35°, it indicates that the powder has good flowability; when α≥35°, it indicates that the powder has poor flowability.
[0137] Table 9 shows the different dosage ratios of micronized silica gel, calculated based on a total weight of 1g of the compound dry suspension.
[0138] Table 9 Different dosages of micronized silica gel
[0139]
[0140] Preparation method:
[0141] 1) Place trichlorobenzazole, levamisole, xanthan gum, micronized silica gel, sucrose and poloxamer 188 in a mortar and grind for 5 minutes respectively;
[0142] 2) After grinding, pass the medicine through a 60-mesh sieve;
[0143] 3) Weigh 0.400g of triclofenac, 0.300g of levamisole, 0.220g of xanthan gum, 1881.000g of poloxamer, and fill each mass of micronized silica gel and sucrose to 10g. Mix them and place them in a stoppered medicine bottle.
[0144] 4) Use a shaking mixer, set the speed to 800 rpm, mix the drug and take 1g to obtain the compound dry suspension.
[0145] The angle of repose and sedimentation volume ratio of each group of compound dry suspensions were measured using the fixed funnel method.
[0146] The results are shown in Table 10 below.
[0147] Table 10. Determination results of different dosages of micronized silica gel
[0148]
[0149] When the dosage of micronized silica gel is 1.0%, 1.2%, 1.4%, and 1.5%, the angle of repose is less than 35°. However, when the dosage is 1.5%, the sedimentation volume ratio is lower than that of the first three groups. Therefore, the preferred dosage of micronized silica gel is 1.0%, 1.2%, and 1.4%.
[0150] orthogonal experiment
[0151] The orthogonal experiment included four factors and three corresponding levels: xanthan gum, poloxamer 188, micronized silica gel, and a blank control. The orthogonal experimental table is as follows:
[0152] Table 11 Orthogonal Experiment Table
[0153]
[0154] The preparation method is the same as above, and the sedimentation volume ratio and redispersibility of the compound dry suspension are determined.
[0155] The results are shown in Table 12 below.
[0156] Table 12 Results of the orthogonal experiment
[0157]
[0158]
[0159] Table 12 shows that the sedimentation volume ratios of the suspensions prepared from the triclofenac-levamisole compound dry suspensions in all nine groups were greater than 0.9, and the dispersion was good, meeting the requirements for dry suspensions. Especially for experimental group 7, the dosage of each main ingredient and excipient was the optimal formulation of this invention: 4% triclofenac, 3% levamisole, 2.4% xanthan gum, 1.0% poloxamer, 1.4% micronized silica gel, and 88.2% sucrose. After standing for 3 hours, the triclofenac-levamisole compound dry suspension in this group showed the largest sedimentation volume ratio, indicating that this suspension had the slowest sedimentation rate and the best stability.
[0160] Dry suspension insecticidal effect test
[0161] Examination, grouping, and administration of parasite eggs in experimental animals
[0162] Before the experiment, feces were collected from each sheep in the sheep farm by digital rectal examination. Parasite eggs were examined using repeated washing and sedimentation and saturated salt flotation methods. Twenty sheep infected with both liver fluke and nematode were selected.
[0163] The repeated washing and sedimentation method is suitable for examining trematode eggs. The specific procedure is as follows: Weigh 5g of sheep feces into a beaker, add 100ml of water, stir thoroughly with a glass rod, filter through a 60-mesh sieve into another beaker, let stand for 30 minutes, discard the supernatant, retain the precipitate, add water again, mix well, and let it settle again. Repeat this process of washing the precipitate with water several times until the supernatant is clear. Finally, discard the supernatant, use a dropper to transfer the precipitate onto a glass slide, cover with a coverslip, and examine under a microscope. Examine and count all precipitates used.
[0164] The saturated saline flotation method is suitable for examining nematode eggs. The specific procedure is as follows: Weigh 5g of feces and add 100ml of saturated saline solution to a beaker. Stir thoroughly with a glass rod, then filter through a 60-mesh sieve into a conical flask (the container should have a small, deep opening and a small volume to maximize egg collection). Let it stand for 30 minutes to allow the eggs to concentrate on the surface. Take a 5mm diameter copper wire ring and hold it parallel to the liquid surface to collect the surface film. Shake it onto a glass slide, cover with a coverslip, and examine under a microscope. Repeat this process for all liquid surfaces until no eggs are detected and count them.
[0165] Triclofenadazole and levamisole in the triclofenadazole-levamisole compound dry suspension were prepared by replacing triclofenadazole and levamisole with sucrose, respectively, to prepare triclofenadazole single-agent dry suspension; levamisole single-agent dry suspension; and a dry suspension containing only excipients but not the two anthelmintic drugs was also prepared.
[0166] Grouping of experimental animals
[0167] Before oral administration of the medication, the sheep were clearly marked for easy identification. The sheep were divided into four groups: a dry suspension containing only excipients, a triclofenac dry suspension, a levamisole dry suspension, and a triclofenac-levamisole compound dry suspension, totaling four deworming groups with five sheep in each group. Feces collected on day 0 of the experiment from the sheep in all four deworming groups served as positive controls (undewormed), and were used for EPG (egg count per gram of feces, unit: eggs·g) before medication. -1 ) Calculation. The feeding conditions and environment for all sheep were the same.
[0168] Administration method in experimental animals
[0169] The experimental dosage of triclobenzazole was 10 mg / kg and levamisole was 7.5 mg / kg. Dry suspensions containing only excipients, triclobenzazole-only dry suspensions, levamisole-only dry suspensions, and triclobenzazole-levamisole compound dry suspensions were prepared into suspensions with mineral water at a ratio of 1:50. The suspensions were administered orally to each group of sheep that had stopped drinking water for 1 day. After administration, the sheep grazed, ate, and drank normally. The sheep's mental state was observed daily and the sheepfold was cleaned once a day.
[0170] Egg counting test method
[0171] Feces were collected from each sheep in the 0d, 7d, and 15d drug administration groups via digital rectal examination. Trematode and nematode eggs were examined and counted microscopically using the repeated washing and sedimentation method and the saturated saline flotation method, respectively. The egg conversion rate and egg reduction rate were calculated using the following formulas:
[0172] The rate of negative conversion of parasite eggs = (number of sheep with negative parasite eggs / number of sheep in each experimental group) × 100% (sheep with zero parasite eggs detected are counted as sheep with negative parasite eggs);
[0173] Egg reduction rate = [(average EPG before deworming - average EPG after deworming) / average EPG before deworming] × 100%.
[0174] The test results are as follows:
[0175] In the four groups of experiments, the EPG values of parasite eggs, the negative conversion rate of parasite eggs, and the reduction rate of parasite eggs were collected from the feces of each group 7 days and 15 days after administration. The results are shown in Tables 13, 14, 15, and 16. Group 1 (dry suspension containing only excipients), Group 2 (triclobendazole single-agent dry suspension), Group 3 (levamisole single-agent dry suspension), and Group 4 (triclobendazole-levamisole compound dry suspension (triclobendazole 4 parts, levamisole 3 parts, xanthan gum 2.4 parts, micronized silica gel 1.4 parts, poloxamer 188 1.0 part, sucrose 88.2 parts)). On days 7 and 15, the negative conversion rate and reduction rate of trematode eggs in groups 1 and 3 were 0%, indicating that the dry suspension excipient and levamisole had no effect on trematode control; the negative conversion rate and reduction rate of nematode eggs in groups 1 and 2 were 0%, indicating that the dry suspension excipient and trichlorobenzazole had no effect on nematode control.
[0176] Triclofenadazole single-agent dry suspension and triclofenadazole-levamisole compound dry suspension showed good anthelmintic effects against sheep flukes. On day 15, the negative conversion rate of eggs in group 2 was 80%, and the egg reduction rate was 99.21±2.00%; in group 4, the negative conversion rate and egg reduction rate were both 100%. Levamisole single-agent dry suspension and triclofenadazole-levamisole compound dry suspension also showed good anthelmintic effects against sheep nematodes. On day 15, the negative conversion rate of eggs in group 3 was 20%, and the egg reduction rate was 99.25±0.53%; in group 4, the negative conversion rate was 40%, and the egg reduction rate was 99.59±0.36%. After 15 days, the triclofenadazole-levamisole compound dry suspension showed good anthelmintic effects against both sheep flukes and nematodes, exceeding 99%. On day 7, the reduction rate of trematode eggs in groups 2 and 4 differed significantly (p<0.05), indicating that sheep treated with the triclofenac-levamisole compound dry suspension showed a significantly higher trematode-detoxifying effect on day 7 compared to sheep treated with triclofenac alone. On day 15, the reduction rate of trematode eggs in groups 2 and 4 was not significant (p>0.05), and the reduction rate of nematode eggs in groups 3 and 4 was also not significant (p>0.05). Furthermore, groups 2, 3, and 4 showed highly significant differences compared to group 1 (the excipient group) (p<0.01), indicating that the combined use of the two treatments did not inhibit the trematode-detoxifying effect. After administration, no adverse reactions were observed in the sheep in any group, and their appetite, mental state, and fecal condition were all normal.
[0177] Table 13. Deworming effect of sheep fluke eggs in each experimental group on day 7 (n=5)
[0178]
[0179] Table 14. Deworming effect of sheep fluke eggs in each experimental group on day 15 (n=5)
[0180]
[0181] Table 15. Deworming effect of sheep nematode eggs in each experimental group on day 7 (n=5)
[0182]
[0183]
[0184] Table 16. Deworming effect of nematode eggs on sheep in each group on day 15 (n=5)
[0185]
Claims
1. A triclabendazole-levamisole combination dry suspension, characterized in that, It is composed of the following main and auxiliary ingredients: 4 parts trichlorobenzazole, 3 parts levamisole, 2.2-2.4 parts suspending agent, 1.0-1.4 parts flow aid, 1.0-1.2 parts emulsifying and wetting agent, and 88.0-88.8 parts sweetener; The suspending agent is xanthan gum; the flow aid is micronized silica gel; the emulsifying wetting agent is poloxamer 188; and the sweetener is sucrose.
2. The triclabendazole-levozole combination dry suspension according to claim 1, characterized in that, It is composed of the following main and auxiliary materials: 4 parts trichlorobenzazole, 3 parts levamisole, 2.4 parts xanthan gum, 1.2-1.4 parts micronized silica gel, 1.0-1.2 parts poloxamer 188, and 88.2-88.4 parts sucrose.
3. The triclabendazole-levozole combination dry suspension according to claim 2, characterized in that, It is composed of the following main and auxiliary materials: 4 parts trichlorobenzazole, 3 parts levamisole, 2.4 parts xanthan gum, 1.4 parts micronized silica gel, 1.0 part poloxamer 188, and 88.2 parts sucrose.
4. The triclabendazole-levozole combination dry suspension according to claim 1, characterized in that, It is a compound dry suspension obtained by grinding each main and auxiliary material separately and passing them through a 60-mesh sieve, mixing the powders obtained by mixing them in the following weight ratios: 4 parts trichlorobenzazole, 3 parts levamisole, 2.2-2.4 parts suspending agent, 1.0-1.4 parts flow aid, 1.0-1.2 parts emulsifying and wetting agent, and 88.0-88.8 parts sweetener, and then shaking them thoroughly to achieve uniformity.
5. A process for the preparation of a triclabendazole-levamisole combined dry suspension according to any one of claims 1 to 4, characterised in that, Includes the following steps: (1) Place the main and auxiliary materials trichlorobenzazole, levamisole, suspending agent, flow aid, emulsifying wetting agent and sweetener in a mortar and grind for 5 minutes to obtain the ground main and auxiliary materials respectively; (2) Pass the ground main and auxiliary materials through a 60-mesh sieve; (3) Weigh the sieved main and auxiliary materials according to the weight ratio described in any one of claims 1-4 and place them in a stoppered medicine bottle; (4) Shake and mix the drug in the bottle to obtain the compound dry suspension.
6. The method of claim 5, wherein, In step (4), oscillation is performed using an oscillating mixer with a rotation speed of 800 rpm.
